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Background: Angiostrongylus cantonensis is a parasite endemic in the Southeast Asian and Pacific regions. Humans
are incidentally infected either by eating uncooked intermediate hosts or by consuming vegetables containing the
living third-stage larvae. The 14-3-3β protein is a cerebrospinal fluid (CSF) marker of neuronal damage during the
development of Creutzfeldt-Jakob disease. In addition, increased 14-3-3β protein is also found in CSF from patients
with a variety of neurological disorders. The goal of this study is to determine the roles of serum/CSF14-3-3β protein
in patients with eosinophilic meningitis.
Methods: In a cohort study among nine Thai laborers with eosinophilic meningitis due to eating raw snails
(Pomacea canaliculata), we examined the CSF weekly while patients were still hospitalized and followed up the
serum for 6 months. The levels of 14-3-3β protein in CSF were analyzed by western blot and an in-house 14-3-3β
enzyme-linked immunosorbent assay (ELISA) measurement was established and tested in an animal model of
eosinophilic meningitis.
Results: The elevated 14-3-3β level was detected in the CSF from eight out of nine (81%) patients After 2 weeks of
treatment, all patients showed a declined level or cleared of 14-3-3β protein in the CSF. By developing an in-house
ELISA for measurement of 14-3-3β protein, it was found that the serum 14-3-3β level was significantly increased in
patients during initial visit. . This finding was consistent to the animal experiment result in which there was severe
blood brain barrier damage three weeks after infection and increased 14-3-3β protein expression in the CSF and
serum by western blot and in house ELISA. After treatment, the serum 14-3-3β level in meningitis patients was
rapidly returned to normal threshold. There was a correlation between initial CSF 14-3-3β level with severity of
headache (r = 0.692, p = 0.039), CSF pleocytosis (r = 0.807, p = 0.009) and eosinophilia (r = 0.798, p = 0.01) in the CSF
of patients with eosinophilic meningitis (Spearman’s correlation test).
Conclusions: The serum 14-3-3β concentrations may constitute a useful marker for blood brain barrier damage
severity and follow up in patients with eosinophilic meningitis caused by A. cantonensis.
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The major cause of eosinophilic meningitis in the Pacific
Islands and Southeast Asia is Angiostrongylus cantonen-
sis, also known as the rat lungworm [1-4]. Humans are
infected with A. cantonensis by ingesting freshwater, ter-
restrial snails and slugs [5-8]. The major intermediate
hosts for A. cantonensis in Taiwan are the African giant
snail (Achutina fulica) and the golden apple snail (Poma-
cea canaliculata) [5,8]. Pomacea canaliculata was intro-
duced to Taiwan in 1979 as a food source. It spread
widely in paddy fields and drainage ditches and has be-
come an important cause of outbreaks of eosinophilic
meningitis [8]. Three outbreaks of eosinophilic meningi-
tis caused by A. cantonensis occurred in Kaohsiung,
Taiwan, in 1998, 1999 and 2001, respectively [9-11].
Most patients (17/22, 77%) were adult male, Thai la-
borers who had eaten raw golden apple snails approxi-
mately 1 to 3 weeks earlier before hospitalization.
The presence of 14-3-3 protein in cerebrospinal fluid
(CSF) has been found to have significant in vivo diagnos-
tic properties in patients with Creutzfeldt-Jakob disease
(CJD) [12], and it is thought to result from neuronal dis-
ruption and the leakage of brain proteins into the CSF
[13]. This protein was found in CSF specimens obtained
from patients with various neurological pathologies
whose common feature was the presence of some degree
of neuronal loss [14-17]. Although its lack of specificity
clearly implies substantial limitations in the use of 14-3-
3 protein as a specific CJD marker, its value as an indica-
tor of neurological damage could be used to monitor the
evolution of different neurological disorders with etiolo-
gies that can be otherwise established. Furthermore, the
14-3-3 protein was recently found to be reacted with 31-
kDa antigen in A. cantonensis infection [18]. Therefore,
it was possible to use this protein as a diagnostic tool in
A. cantonensis infection.
Based on this hypothesis, we studied the dynamic
changes of 14-3-3β protein expression in the second
outbreak, correlated with CSF findings and established
the measurement of 14-3-3β protein expression by
enzyme-linked immunosorbent assay (ELISA) and tested
in an animal model of eosinophilic meningitis.
Methods
Ethics statement
All of the samples of human patients (A to I) were ob-
tained from an outbreak of eosinophilic meningitis in
1999. Those samples were collected at the research labora-
tory of Infectious Diseases Department, Kaohsiung Vet-
erans General Hospital (KVGH) and the patient’s
information was delinked. Institutional review board (IRB)
approval to use the samples was obtained from the Com-
mission on Medical Ethics of the Kaohsiung Veterans
General Hospital (VGHKS98-CT8-07). All participantswere informed about the study procedures and gave their
written informed consent initially when the outbreak oc-
curred. Animal studies were carried out in strict accord-
ance with the recommendations from Taiwan’s Animal
Protection Act. The protocol was approved by the Animal
Committee of the Kaohsiung Veterans General Hospital.
Study population
A case of eosinophilic meningitis was clinically defined
as an acute onset of headache, eosinophil pleocytosis in
the blood/CSF, accompanied by at least of one of the fol-
lowing: fever, ataxia, visual disturbances, photophobia,
nuchal rigidity, neck pain, hyperesthesias, or paresthesias
[10]. All patients who had eaten raw snails within
3 weeks of the outbreak’s onset were included in the
study. We recorded demographic information, the date
of snails were eaten and the amount ingested, clinical
symptoms, and prior parasitic infections. Each patient
underwent a physical, neurologic, and ophthalmic exam-
ination. The headache intensity was rated on a 4-point
scale ranging from none to severe (0 = none, 1+ =mild,
2+ =moderate, 3+ = severe) [10]. The hyperintense basal
ganglia lesion on T1-weighted MRI was also graded as a
4-point scale ranging from none to severe by 2 inde-
pendent radiologists [10]. Spinal taps were performed on
all patients. The patients were observed daily during their
hospital course. CSF was examined weekly. Peripheral
blood was obtained weekly for the first 2 months, every
other week for the next 2 months, and monthly there-
after for as long as 6 months. Antibodies to A. cantonen-
sis were detected in serum and CSF by a microenzyme-
linked immunosorbent assay (ELISA) using young-adult
worm antigen, molecular weight 204 kDa purified by
monoclonal antibody [19].
Infection of Balb/C mice with third stage larvae of A.
cantonensis
Twenty-four Balb/C mice, aged 6–7 weeks, were pur-
chased from the National Laboratory Animal Breeding
Research Centre. They were raised and maintained in an
air-conditioned animal facility (25 ± 2°C and 50 ± 10%
relative humidity). Third-stage larvae of A. cantonensis
were harvested from infected Biomphalaria glabrata
after treatment with artificial gastric juice (pepsin, 2 g;
concentrated HCl, 7 mL; distilled water, 1 L). Mice were
orally infected with 50 A. cantonensis L3 via an orogas-
tric tube after slight ether anesthesia and then mice were
euthanized every week for 3 consecutive weeks after
infection.
Collection of serum and CSF specimens
Blood samples from experimental mice were collected by
a heart puncture under ketamine anesthesia. Serum spec-
imens separated from blood samples after centrifugation
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were stored at − 70°C until they were measured.
The skull of the mice was opened after complete
bleeding. Careful surgery was conducted in order to
avoid blood contamination of the CSF. The brain was re-
moved and washed with 50 μL 0.15 M phosphate buff-
ered saline (PBS). Concurrently, the cerebral ventricles
and cranial cavity were washed with 350 μL PBS. The
CSF was, thus, harvested with PBS from above, which
was then centrifuged in an eppendorf tube at 3000 × g
(Hermle, Z326K, Germany) for 10 min at 4°C to elimin-
ate cells. The supernatant was stored at −70°C until fur-
ther use.
Measurement of permeability of the blood–brain barrier
by Evans blue method
Evans blue was used to assess the permeability of the
blood–brain barrier to macromolecules. When the
blood–brain barrier had been compromised, albumin-
bound Evans blue entered the CNS. In brief, a volume of
200 μL of 2% (w/v) solution of Evans blue in PBS was
injected into the tail vein of a mouse. One hour later the
brain of the mouse was removed after anesthesia with
ketamine, which was ground with 1.0 mL PBS in a glass-
tissue grinder with a Teflon pestle. The extract was then
centrifuged at 18,000 × g (Hermle, Z326K, Germany) for
10 min at room temperature. The optical density (OD) of
the supernatant was read at 595 nm wavelength using a
colorimeter (Thermo scientific multiskan FC, USA).
Then the OD values of mice brain supernatant after 1 to
3 weeks infections were compared with the control.
Measurement of 14-3-3β protein concentrations in
CSF/serum by Western blot analysis
CSF/serum aliquots of 100 μL from 9 patients and
mice were mixed with 7 volumes of cold methanol, kept
at -20°C for 2 h, and then centrifuged at 20,800 g for
30 min. The pellet was dissolved in 40 μL of sample buffer
(3% SDS, 3% β-mercaptoethanol, 2 mM EDTA, 10% gly-
cerol, and 62.5 mM Tris, pH, 6.8) and boiled for 5 min.
For each sample, 10 μL (the equivalent of 25 μL of CSF),
5 mL, and 1.25 mL of sample buffer/well were loaded onto
a 13% polyacrylamide gel and transferred to polyvinyliden
difluoride membranes (Immobilon P; Millipore). Mem-
branes were incubated with anti 14-3-3β polyclonal
rabbit IgG (Santa Cruz Biotechnology) at a 1:500 dilution
and revealed with anti-rabbit horseradish peroxidase IgG
(Amersham) at a 1:3000 dilution. The blots were de-
veloped using an enhanced chemiluminescent system
(Amersham). Densitometric values for each sample were
obtained with a computer-assisted laser scanner (GS-710
Calibrated Imaging Densitometry; BioRad), after correc-
tion for background. The total amount of 14-3-3 protein
as quantified from each diluted and undiluted CSFsample was expressed in arbitrary units [19]. The human
control group (n = 9), matched for age and gender, con-
sisted of patients with headache or altered consciousness
who underwent lumbar puncture to exclude meningitis.
CSF samples were centrifuged and the supernatants were
frozen at −80°C until assayed.
Generation of recombinant 14-3-3β
Recombinant human 14-3-3β protein was purified from E.
coli for antibodies generation as previously described [20].
The human 14-3-3β cDNA was amplified from a human
fetal brain cDNA library (Stratagene, La Jolla, CA) using
the polymerase chain reaction (PCR). The PCR primers
used to clone the human 14-3-3β cDNA were designed
based on the 14-3-3β sequence in the Gen-Bank database
(accession number, NM_003404.3; forward primer, 5′-
cgcggatccatgacaatggataaaagtgagctg −3′; reverse primer, 5′-
ggcgaattcttagttctctccctccccagc-3′). After DNA sequencing
analysis, the PCR-amplified 14-3-3β cDNA was subcloned
into the EcoRI and BamHI sites of the pET28a vector
(Novagen, Madison, WI) and transformed into BL-21 cells
(DE3, pLysS; Novagen). After induction, the 6x-histidine-
tagged 14-3-3β protein was purified on an NTA-agarose
affinity column (Qiagen, Hilden, Germany) and desalted
on a G25 Sephadex column (Amersham Pharmacia, Little
Chalfont, United Kingdom). The recombinant protein was
passed through Detoxi-Gel (Pierce Biotechnology, Rock-
ford, IL) to minimize contamination by endotoxin. The
14-3-3β antibodies were raised by periodic injection of re-
combinant 14-3-3β protein into rabbits. The serum was
collected from immunized rabbits and analyzed using
Western blot analysis.
Production of anti-human 14-3-3β polyclonal antisera
Primary immunization
Purified recombinant 14-3-3β protein in PBS (500 μg in
500 μl) is mixed with complete Freunds adjuvant in a
three-way stopcock until mixture becomes emulsified.
The mixture is then transferred to a 3 ml 24-gauge syr-
inge and was injected subcutaneously into adult New
Zealand white rabbits (2 to 5 kg body weight) under re-
strain. Two weeks after the primary immunization, the
rabbits were then boosted with recombinant 14-3-3β
protein mixed with incomplete Freunds adjuvant at 2-
week intervals for a total of nine boosts.
Blood serum preparation
Blood was collected from the ear marginal veins of re-
strained rabbits before immunization (pre-immune
serum) and after subsequent boosts for a total of six
batches. About 50 ml of blood was collected during each
interval. After removing blood clots, the serum samples
were placed overnight in 4°C and centrifuged 10 minutes
at 5,000 g to remove red blood cell pellets and other cell
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Antibody purification
Serum samples containing 14-3-3β antibodies were puri-
fied using Protein A column (Pharmacia Biotech) and
quantified with Coomassie Plus Bradford assay kit
(Pierce, #23236). Antibody efficacy was checked with
Western blot analysis using recombinant 14-3-3β pro-
tein at concentration of 1, 0.1 and 0.01ug/ml.
14-3-3β enzyme-linked immunosorbent assay (ELISA)
The in-house 14-3-3β ELISA consisted of rabbit anti-14-
3-3β polyclonal antibody as the capture antibody and
mouse anti-14-3-3β IgG conjugated with horse-radish
peroxidase (Santa Cruz Biotechnologies Inc.; sc-1657
HRP (H-8), 200 μg/ml) as the detection antibody, with
the purified recombinant 14-3-3β protein as standard.
Briefly, 96-well plate were coated with 50 μl per well of
diluted capture antibody (2.5 μg/ml) overnight at 4°C.
After washing with buffer containing 0.05% Tween 20 in
PBS, wells were blocked with buffer containing 0.05%
Tween 20, 0.1% BSA, 5% sucrose in PBS at room
temperature for 30 min. The CSF/serum samples (50 μl)
or standards were applied to wells and incubated at
room temperature for 1 hour. After wash, the wells were
incubated with detection antibody (mouse anti-14-3-3β,
1 μg/ml) at room temperature for 1 hour. Finally, 100 μl
of TMB substrate solutions were added and reacted at
room temperature for 20 min. After adding 50 μl of 2 N
H2SO4, the optical density in each well was measured at
450 nm using an ELISA reader.
Statistical analysis
The relation between the amount of 14-3-3β protein in
CSF, laboratory abnormalities, and clinical severity and
MRI findings were analyzed with Spearman’s correlation
coefficient test. Wilcoxon signed-rank test was used to
compare the change of 14-3-3β protein in every week of
lumbar puncture. Mann Whitney U test was used to
compare the changes of 14-3-3β protein or Evans blue
in third week relative to the controls. A P value <0.05
was considered statistically significant.
Results
In the current studies, all nine patients were young Thai
men. The source of epidemic was ingestion of raw snails
seasoned with lemon juice and red pepper. Antibodies
to A. cantonensis were detected at the time of admission
in the serum of 9 (100%) patients and in the cerebro-
spinal fluid of 4 (44%) patients. Patients in this outbreak
in 1999 only received supportive therapy (acetamino-
phen and naproxen), lumbar puncture was done when
clinically indicated. None received steroid treatment. Allof the nine patients received a total of 23 lumbar punc-
tures. Patient F received a total of 3 lumbar punctures.
Patient C and I have 4 lumbar punctures due to recur-
rent symptoms. Headache, stiff neck, transient right fa-
cial palsy, ataxia, and diplopia recurred in patient C
2 weeks after last admission; he was treated with intra-
venous glycerol for 7 days and recovered completely.
Vomiting and headache developed in patient I 3 weeks
after admission and a spinal tap revealed an elevated
opening pressure of 240 mm H2O, a white cell count of
1110 × 103 cells per μL with 74% eosinophils. He recov-
ered without treatment in about a week.
The Western blot analysis for 14-3-3β protein in CSF
was shown in Figure 1. Eight out of nine patients had a
Detectable 14-3-3β protein in CSF at admission. The ini-
tial 14-3-3β protein amount in CSF, severity of headache,
laboratory abnormalities, and findings in the brain MRI
scan are listed for each patient in Table 1. There was a
correlation between initial CSF 14-3-3β level with sever-
ity of headache (r = 0.692, p = 0.039), CSF pleocytosis
(r = 0.807, p = 0.009), and CSF eosinophilia (r = 0.798,
p = 0.01) in patients with eosinophilic meningitis (Spear-
man’s correlation test). Wilcoxon signed-rank test was
used to compare the change of 14-3-3β protein in each
lumbar puncture and it revealed there was a significant
decrease of 14-3-3 protein amounts in the 2nd week (one
week) after admission (Wilcoxon signed-rank test, p =
0.025). Patient C and I had only mild elevation of 14-3-3
protein when recurrence of symptoms. Nine patients
with a diagnosis of sepsis underwent lumbar puncture
for excluding meningitis as control group all showed
negative 14-3-3β protein expression in CSF and serum.Detection of 14-3-3β levels in patient CSF/Serum samples
Using polyclonal antibodies constructed from rabbit im-
munized with recombinant 14-3-3β antigen, we have
established a procedure to detect 14-3-3β levels in CSF
and serum using ELISA. We have found that the level of
14-3-3β protein in the patient serum decreased over an
eight week period after on admission to the hospital
(Figure 2). There was a near four-fold reduction of the
protein at about two weeks after the first lumbar puncture
(Wilcoxon signed-rank test, p = 0.012). However, we did
not observe significant changes in the CSF samples due to
the inadequate samples numbers and CSF volumes.Permeability of the blood–brain barrier by Evans blue
method in the animal study
Uninfected control mice with the optical density of the ex-
tract of the brain measured at 595 nm were similar with
the blank control. In contrast, the brain of infected mice
showed varying degrees of staining by Evans blue after in-
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Figure 1 Dynamic changes of 14-3-3β protein expression in 9 patients with eosinophilic meningitis. A) Expression of 14-3-3β protein in
the CSF of patients with eosinophilic meningitis after visits for treatment. Numbers indicate time intervals of lumbar punctures (units are in
weeks). Eight out of nine patients show detectable level of 14-3-3β protein on admission at the hospital. Lumbar punctures performed on one
week after admission show decreased expression in the CSF (Wilcoxon signed-rank test, p = 0.025). B) Expression profile of 14-3-3β protein in
patient I. It showed clearance of CSF 14-3-3β protein 3 weeks after presentation (1: admission; 2: One week after presentation; 3: Two weeks after
presentation; 4: Three weeks after presentation).
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pared to those of uninfected mice (p = 0.028) Figure 3.
Western blot analysis of 14-3-3β protein in the CSF/serum
of mice
The Western blot analysis for 14-3-3β protein expres-
sion in the CSF/serum of mice was shown in Figure 4.
There was a significant increase of 14-3-3β protein
amounts of serum/CSF in the 3rd week after infection
compared to control. This finding was consistent the se-
verity of blood brain barrier damage as evidence by the
Evans Blue assay result.Table 1 Initial 14-3-3β protein amount and laboratory and m
sinophilic meningitis caused by A. cantonensis
Blood
Patient White blood cell count Eosinophil Protein Glucose Wh
(×103/μL) (%) (mg/dL) (mg/dL)
A 8210 8 67 75
B 7570 10 49 60
C 10500 36 154 36
D 6990 16 36 66
E 5920 7 95 72
F 9480 16 347 45
G 6490 20 50 71
H 8510 2 27 70
I 13270 29 201 59
ME: meningeal enhancement; MRI: magnetic resonance imaging; Severity of headac
grading is as follows: 0 none, 1+ mild, 2+ moderate, 3+ high signal intensity in bila
supportive treatment (acetaminophen and naproxen), lumbar puncture was done wDetection of 14-3-3β levels in mice CSF/Serum samples
by in house ELISA
Using polyclonal antibodies constructed from rabbit im-
munized with recombinant 14-3-3β antigen, we have
established a procedure to detect 14-3-3β levels in CSF
and serum using ELISA. We found that the level of 14-
3-3β protein in the CSF/serum increased over a three
week period after infection Figures 5 and 6.
Discussion
We found that the amounts of CSF 14-3-3β protein were
increased in our patients at presentation. After 2 weeksagnetic resonance imaging scan findings in 9 cases of eo-
Cerebrospinal fluid
ite blood cell count Eosinophil 14-3-3β Headache
(×103/μL) (%) Protein(DU) severity MRI
1 0 6.8 1 ME, 1+
0 0 1.1 1 ME, 1+
1270 36 0 3 ME, 3+
139 6 9.8 1 ME, 2+
9 0 0 1 ME, 1+
1660 6 7.8 3 ME, 2+
1 0 0 1 ME, 1+
0 0 0 2 ME, 2+
1390 17 5.1 3 ME, 2+
he is graded as follows: 0 none, 1+ mild, 2+ moderate, 3+ severe. The MRI
teral globus pallidus on T1 imaging. All of the 9 patients received only
hen clinically indicated.
***
***  p <0.001
Figure 2 Concentration of 14-3-3β proteins in the patient
serum samples. Each weekly interval contain the collective serum
samples taken from the nine patients at that particular time period.
ELISA analysis performed on the serum samples showed significant
decrease in 14-3-3β protein levels 2 weeks after admission (Wilcoxon
signed-rank test, p = 0.012). 1: admission; 3: Two weeks after
presentation; 6: Five weeks after presentation; 9: Eight weeks after
presentation). One patient had no follow up data.
CSF(30kd) 
Serum (30kd) 
Figure 4 Expression of 14-3-3β protein in the serum and CSF of
mice with eosinophilic meningitis by the western blot assay.
There was a significant increase of 14-3-3β protein amounts of
serum/CSF in the 3rd week after infection compared to the controls.
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cleared of 14-3-3β protein in the CSF. We also found
that the serum 14-3-3β level was significantly increased
in patients during initial visit by our in house ELISA.
This probably indicated that the leakage of 14-3-3β from
the brain because of neuronal damage and blood brain
barrier dysfunction. This finding was consistent to the

















Figure 3 Dynamic changes of Evans blue amounts in mice with
eosinophilic meningitis caused by A. cantonensis infection. The
amount of Evans blue in the mice brain showed significantly
increase 3 weeks after infection compared to those of uninfected
mice (p = 0.028).blood brain barrier damage three weeks after infection
and increased 14-3-3β protein expression in the CSF
and serum by western blot and in house ELISA.
The 14-3-3 proteins belong to a family of acidic, di-
meric proteins that are expressed in all eukaryotic cells.
This family of highly conserved proteins plays crucial
roles in regulating multiple cellular processes including
the maintenance of cell cycle checkpoints and DNA re-
pair, the prevention of apoptosis, the onset of cell differ-
entiation and senescence, and the coordination of cell
adhesion and motility [21]. The highest tissue concentra-
tion of 14-3-3 proteins is found in the brain, comprising
about 1% of its total soluble protein [22] and being
present in the cytoplasmic compartments, plasma mem-
brane and in intracellular organelles [23]. In addition to
their possible role in neuronal function, 14-3-3 proteins
have attracted much recent interest owing to their pos-
sible involvement in the pathophysiology of various
neurological disorders [14-17,24]. However, there had
been no reports in the literature that deal with the asso-
ciation of 14-3-3 protein and eosinophilic meningitis
caused by A. cantonensis. In our cohort study, nine pa-
tients with eosinophilic meningitis, in addition to the
commonly tested CSF parameters, were serially mea-
sured the CSF concentrations of 14-3-3β proteins. Most
of the patients (8/9, 90%) whom we investigated had a
positive test result at admission, and all of those who re-
covered cleared 14-3-3β protein from CSF 2–3 weeks
after hospitalization. This dynamic change of 14-3-3β
protein in CSF was consistent to the clinical course of
recovery in our patients who received 2 weeks of treat-
ment of painkiller and serial spinal tapping [9]. If 14-3-
3β proteins in CSF were used to monitor the evolution
of a reversible condition, a marker of tissue damage
must quickly clear once the damaging process has sub-
sided, as in our cases.
We found a fairly good sensitivity of the 14-3-3β test.
This result, however, had weak significance because
they were based on only 9 patients with eosinophilic



























Figure 5 The levels of 14-3-3β protein in the CSF increased over a three week period after infection and the data was shown by an in
house ELISA.
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homogenous population, regularly monitored CSF dy-
namic change and excluded patients with other neuro-
logical conditions such as other infectious encephalitis,
dementia, brain tumor, metabolic encephalopathy, neur-
opathy and Creutzfeldt-Jakob disease, that would other-
wise cause elevation of 14-3-3β protein in CSF [12-17].
























Figure 6 The levels of 14-3-3β protein in the serum increased over a
in house ELISA.storage of CSF samples may alter the results of the test
[13]. In our study, lumbar puncture techniques were op-
timal and identical in each case. The possible reason
explaining the only one negative test result could be in-
appropriate handling and storage of CSF, technical prob-
lem, and threshold of 14-3-3 protein detection. Another
most importantly reason was that the patient (patient H)
was diagnosed as A. cantonensis infection only based on2 week 3 week
=0.015 
three week period after infection and the data was shown by an
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had no peripheral eosinophilia or CSF abnormalities
which are commonly seen in patients with eosinophilic
meningitis caused by A. cantonensis infection. Finally,
the time interval between disease onset and the 14-3-3β
test was similar in the eosinophilic meningitis group and
control group (13 vs.12 days, respectively), suggesting
that disease duration alone cannot account for the dy-
namic change of 14-3-3β protein in CSF. Taken together,
our data suggest that, when performed as a screening
test in a patient with eosinophilic meningitis, a positive
14-3-3β test result may rule in this diagnosis. Another
matter of concern comes from the questionable reliabil-
ity of the 14-3-3β test, because in two of our patients
with relapse (patient C, I), the result was found to be
first positive and then only weakly positive when relapse
occurred. This situation does not seem to be unique be-
cause it has already been observed by others in four
non-CJD patients who were initially found positive and
then negative 2 weeks later [25]. Possible explanations
include instability of the 14-3-3β protein in the sample
over time, or clinical recurrence of symptoms/signs
which did not cause ongoing neuronal damage. To solve
these issues, further controlled, multicenter studies
assessing the validity of the 14-3-3β test are needed.
Identification of 14-3-3 proteins in CSF of patients
afflicted with a wide range of neuro-degenerative dis-
eases has been well documented [17,26], however there
is few literatures which discuss the presence of such pro-
tein in the serum. In the current study, we presented the
in-house ELISA as another diagnostic mean to validate
the western blot analysis of 14-3-3β proteins in the CSF
and serums samples collected. We found that there was
a significant decrease in serum 14-3-3β level from onset
of meningitis to two weeks after admission to the hos-
pital, and so on until 8th week. However, there were no
significant changes in CSF 14-3-3β levels between each
lumbar puncture intervals as opposed to results from
western blot. It is likely that limited CSF sample num-
bers and inadequate CSF volumes for ELISA contributed
to such discrepancy, as the results from ELISA would be
less accurate and sensitive if there weren’t enough sam-
ples available for analysis.
The presence of 14-3-3β proteins in serum samples
may be the consequences of disruption of the blood
brain barrier caused by the meningitis, as it was shown
that infection by the parasite may induce up-regulation
of inflammatory agents such as MMP-9 [27], and con-
tributes to the degradation of meningeal blood vessel
membranes. This change in the cerebral vasculature
could account for the leakage of 14-3-3β, primarily a
CNS protein, into the peripheral circulation. In terms of
clinical application, the ability to detect 14-3-3β proteins
in serum samples may yield potential diagnostic valuessuch ease of sample acquisition, reduced discomfort for
patients undergoing diagnosis and increased efficiency in
sample handling/detection. However, the current tech-
nique may require additional refinements to increase its
sensitivity and accuracy before it could be implemented
as an alternative diagnostic tool of neurodegenerative
disease.
Conclusion
The current study found that patients with eosinophilic
meningitis and presence of 14-3-3β proteins in CSF
tended to have more severe CSF laboratory abnormal-
ities. The decline of 14-3-3β proteins 2–3 weeks after
admission was consistent with the idea that 14-3-3 pro-
tein levels are associated with the pace of neuronal
injury.
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